Диссертация (1155054), страница 31
Текст из файла (страница 31)
22 /H.G. Brittain. – Academic press, 1993. – 153 p.50. Camacho K.M. Low-molecular-weight polymer?drug conjugates for synergisticanticancer activity of camptothecin and doxorubicin combinations / K.M. Camacho, S.Menegatti, S. Mitragotri // Nanomedicine. – 2016. – Vol. 11.
– № 9. – P. 1139-1151doi:10.2217/nnm.16.33.51. Casulo C. Non-Hodgkin lymphoma / C. Casulo, L. Rich. – NY 10605, 2013. –56 p.52. Cazes J. Thin Layer Chromatography in Phytochemistry : ChromatographicScience Series. Vol. 99 / J. Cazes; eds. M. Waksmundzka-Hajnos, J. Sherma, T.Kowalska. – CRC Press, 2008. – 888 p. doi:10.1201/9781420046786.53. CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer cells / H.
Onishi, K.Suyama, A. Yamasaki [et al.] // Anticancer Research. – 2017. – Vol. 37. – № 2. – P.561-566 doi:10.21873/anticanres.11349.54. Cell-based drug delivery / F. Pierigè, S. Serafini, L. Rossi [et al.] // Advanced drugdeliveryreviews.–2008.–Vol.
60.–№ 2.–P. 286-95doi:10.1016/j.addr.2007.08.029.55. Cell Based Drug Delivery System through Resealed Erythrocyte - A Review / A.Gupta, a K. Mishra, P. Bansal [et al.] // International Journal of PharmaceuticalSciences and Drug Research. – 2010. – Vol. 2.
– № 1. – P. 23-30.56. Characterization of highly stable liposomal and immunoliposomal formulations ofvincristine and vinblastine / C.O. Noble, Z. Guo, M.E. Hayes [et al.] // CancerChemotherapy and Pharmacology. – 2009. – Vol. 64. – № 4. – P. 741-751doi:10.1007/s00280-008-0923-3.57. Characterization of PEGylated nanoliposomes co-remotely loaded with topotecanand vincristine: relating structure and pharmacokinetics to therapeutic efficacy / D.191Zucker, A.
V. Andriyanov, A. Steiner [et al.] // Journal of Controlled Release. – 2012.– Vol. 160. – № 2. – P. 281-289 doi:10.1016/j.jconrel.2011.10.003.58. Chitosan-based intelligent theragnosis nanocomposites enable pH-sensitive drugrelease with MR-guided imaging for cancer therapy / E.-K. Lim, W. Sajomsang, Y.Choi [et al.] // Nanoscale Research Letters. – 2013.
– Vol. 8. – № 1. – P. 467doi:10.1186/1556-276X-8-467.59. Cimpan G. Analysis of medicinal plants by HPLC: Recent approaches / G.Cimpan, S. Gocan // Journal of Liquid Chromatography & Related Technologies. –2002. – Vol. 25. – № 13-15. – P. 2225-2292 doi:10.1081/JLC-120014003.60. Comparison of Conventional Chemotherapy, Stealth Liposomes and TemperatureSensitive Liposomes in a Mathematical Model / A. Gasselhuber, M.R. Dreher, F.Rattay [et al.] // PLoS ONE. – 2012.
– Vol. 7. – № 10. – P. e47453doi:10.1371/journal.pone.0047453.61. Conversion of encapsulated 5-fluoro-2’-deoxyuridine 5’-monophosphate to theantineoplastic drug 5-fluoro-2’-deoxyuridine in human erythrocytes. / a De Flora, E.Zocchi, L. Guida [et al.] // Proceedings of the National Academy of Sciences.
– 1988.– Vol. 85. – № 9. – P. 3145-3149 doi:10.1073/pnas.85.9.3145.62. Cytochrome P450-inducing antiepileptics increase the clearance of vincristine inpatients with brain tumors. / K. Villikka, K.T. Kivistö, H. Mäenpää [et al.] // Clinicalpharmacology and therapeutics.
– 1999. – Vol. 66. – № 6. – P. 589-93doi:10.1053/cp.1999.v66.103403001.63.Cytotoxicactivityof2-Fluoro-ara-AMPand2-Fluoro-ara-AMP-loadederythrocytes against human breast carcinoma cell lines. / F. Pierigè, C. De Marco, N.Orlotti [et al.] // International journal of oncology. – 2010. – Vol. 37. – № 1. – P.
13342 doi:10.3892/ijo_00000661.64. Dandamudi S. The drug loading, cytotoxicty and tumor vascular targeting192characteristics of magnetite in magnetic drug targeting / S. Dandamudi, R.B. Campbell//Biomaterials.–2007.–Vol. 28.–№ 31.–P. 4673-4683doi:10.1016/j.biomaterials.2007.07.024.65. Daunorubicin and vincristine binding to plasma membrane vesicles fromdaunorubicin-resistant and wild type Ehrlich ascites tumor cells / M.
Sehested, N.Bindslev, E.J. Demant [et al.] // Biochemical pharmacology. – 1989. – Vol. 38. –№ 18. – P. 3017-27.66. Delivering Nanoparticles to Lungs while Avoiding Liver and Spleen throughAdsorption on Red Blood Cells / A.C. Anselmo, V. Gupta, B.J. Zern [et al.] // ACSNano. – 2013. – Vol. 7. – № 12. – P. 11129-11137 doi:10.1021/nn404853z.67. Delivery of vincristine sulfate-conjugated gold nanoparticles using liposomes: alight-responsive nanocarrier with enhanced antitumor efficiency / N. Feng, Y.
Liu, M.He [et al.] // International Journal of Nanomedicine. – 2015. – Vol. 10. – P. 3081doi:10.2147/IJN.S79550.68. Determination of vinblastine in tumour tissue with liquid chromatography–highresolution mass spectrometry / T. Kosjek, T. Dolinšek, D. Gramec [et al.] // Talanta. –2013. – Vol. 116. – P. 887-893 doi:10.1016/j.talanta.2013.08.009.69. Development of novel self-assembled DS-PLGA hybrid nanoparticles forimproving oral bioavailability of vincristine sulfate by P-gp inhibition / G. Ling, P.Zhang, W. Zhang [et al.] // Journal of Controlled Release.
– 2010. – Vol. 148. – № 2. –P. 241-248 doi:10.1016/j.jconrel.2010.08.010.70. Development of Pegylated Liposomal Vincristine Using Novel Sulfobutyl EtherCyclodextrin Gradient: Is Improved Drug Retention Sufficient to Surpass DSPE–PEGInduced Drug Leakage? / J. Cui, C. Li, C. Wang [et al.] // Journal of PharmaceuticalSciences. – 2011. – Vol. 100. – № 7. – P. 2835-2848 doi:10.1002/jps.22496.71.
Diet-induced obesity alters vincristine pharmacokinetics in blood and tissues of193mice / J.W. Behan, V.I. Avramis, J.P. Yun [et al.] // Pharmacological Research. –2010. – Vol. 61. – № 5. – P. 385-390 doi:10.1016/j.phrs.2010.01.007.72. DNA-Based Hybrid Liquid Crystalline Nano Organometallic Composites forTargeted Drug Delivery in Neutron Capture Therapy / A.I. Slivkin, O.V. Kondrashina,M.A.J.
Halahakoon [et al.] // International Journal of Pharmacy and PharmaceuticalSciences. – 2017. – Vol. 9. – № 6. – P. 74 doi:10.22159/ijpps.2017v9i6.17991.73. Dobson J. Magnetic nanoparticles for drug delivery / J. Dobson // DrugDevelopment Research. – 2006. – Vol. 67. – № 1. – P. 55-60 doi:10.1002/ddr.20067.74.
Drapeau D. Liquid chromatographic isolation of vincristine and vinblastine / D.Drapeau, H.W. Blanch, C.R. Wilke // Journal of Chromatography A. – 1987. –Vol. 390. – № 2. – P. 297-306 doi:10.1016/S0021-9673(01)94383-3.75. Drug-carrier potential of liposomes in cancer chemotherapy / G. Gregoriadis, E.J.Wills, C.P. Swain [et al.] // Lancet (London, England). – 1974. – Vol.
1. – № 7870. –P. 1313-6 doi:10.1016/S0140-6736(74)90682-5.76. Drug, enzyme and peptide delivery using erythrocytes as drug carrier / K.R.Jadhav, S. V. Sankpal, S.M. Gavali [et al.] // International Journal of PharmaceuticalSciences Review and Research. – 2012. – Vol. 12.
– № 1. – P. 79-88doi:10.1016/j.jconrel.2003.11.018.77. Drug Delivery : Handbook of Experimental Pharmacology. Vol. 197 / ed. M.Schäfer-Korting. – Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. – 506 p.doi:10.1007/978-3-642-00477-3.78. Drug delivery systems: An updated review / G. Tiwari, R. Tiwari, S. Bannerjee [etal.] // International Journal of Pharmaceutical Investigation. – 2012.
– Vol. 2. – № 1. –P. 2 doi:10.4103/2230-973X.96920.79. Drug Delivery with Carbon Nanotubes for In vivo Cancer Treatment / Z. Liu, K.Chen, C. Davis [et al.] // Cancer Research. – 2008. – Vol. 68. – № 16. – P. 6652-6660doi:10.1158/0008-5472.CAN-08-1468.19480. Drug Loaded Erythrocytes: As Novel Drug Delivery System / R. Hirlekar, P. Patel,N. Dand [et al.] // Current Pharmaceutical Design. – 2008. – Vol. 14. – № 1. – P.
6370 doi:10.2174/138161208783330772.81. Effect of CYP3A5 expression on vincristine metabolism with human livermicrosomes. / J.B. Dennison, D.R. Jones, J.L. Renbarger [et al.] // The Journal ofpharmacology and experimental therapeutics. – 2007. – Vol. 321. – № 2. – P. 553-63doi:10.1124/jpet.106.118471.82.
Effect of vinca alkaloids on ER-alpha levels and estradiol-induced responses inMCF-7 cells / C. Martínez-Campa, P. Casado, R. Rodríguez [et al.] // Breast cancerresearch and treatment. – 2006. – Vol. 98. – № 1. – P. 81-9 doi:10.1007/s10549-0059134-3.83. ElBayoumi T.A. Current Trends in Liposome Research / T.A. ElBayoumi, V.P.Torchilin // Liposomes Methodsand Protocols Volume 1: PharmaceuticalNanocarriers / eds. V. Weissig, Department. – Totowa, NJ: Humana Press Inc., 2010.
–Vol. 1. – P. 1-29.84. Electrochemical detection of indole alkaloids of Catharanthus roseus in highperformance liquid chromatography / T. Naaranlahti, V.P. Ranta, P. Jarho [et al.] //The Analyst. – 1989. – Vol. 114. – № 10. – P. 1229-31.85. Encapsulation of doxorubicin in liver-targeted erythrocytes increases thetherapeutic index of the drug in a murine metastatic model / E. Zocchi, M. Tonetti, C.Polvani [et al.] // Proceedings of the National Academy of Sciences of the UnitedStates of America.
– 1989. – Vol. 86. – № 6. – P. 2040-4.86. Encapsulation of drugs in intact erythrocytes: An intravenous delivery system / E.Pitt, C.M. Johnson, D.A. Lewis [et al.] // Biochemical Pharmacology. – 1983. –Vol. 32. – № 22. – P. 3359-3368 doi:10.1016/0006-2952(83)90363-5.87. Engineering erythrocytes for the modulation of drugs and contrasting agentspharmacokinetics and biodistribution / L. Rossi, F.
Pierigè, A. Antonelli [et al.] //AdvancedDrugDeliveryReviews.–2016.–Vol.106.–P.73-87195doi:10.1016/j.addr.2016.05.008.88. EryDelSPA. EryDex System [Электронный ресурс] / EryDelSPA. – URL:http://www.erydel.com/public/sitemin/Attest_study_start_up.pdf.–(датаобращения:10.2.2017).89. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimeticdelivery platform / C.-M.J.
Hu, L. Zhang, S. Aryal [et al.] // Proceedings of theNational Academy of Sciences. – 2011. – Vol. 108. – № 27. – P. 10980-10985doi:10.1073/pnas.1106634108.90. Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond /C.H. Villa, D.B. Cines, D.L. Siegel [et al.] // Transfusion Medicine Reviews. – 2017. –Vol. 31.
– № 1. – P. 26-35 doi:10.1016/j.tmrv.2016.08.004.91. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms / A. Weissferdt, J.Fujimoto, N. Kalhor [et al.] // Modern Pathology. – 2017. – Vol. 30. – № 6. – P. 826833 doi:10.1038/modpathol.2017.6.92. Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles /F. Alexis, E. Pridgen, L.K. Molnar [et al.] // Molecular Pharmaceutics.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
